Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 49, 1465-1469, March 15, 1989]
© 1989 American Association for Cancer Research
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jaxel, C.
Right arrow Articles by Pommier, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jaxel, C.
Right arrow Articles by Pommier, Y.

Structure-Activity Study of the Actions of Camptothecin Derivatives on Mammalian Topoisomerase I: Evidence for a Specific Receptor Site and a Relation to Antitumor Activity

Christine Jaxel, Kurt W. Kohn, Mansukh C. Wani, Monroe E. Wall and Yves Pommier1

Laboratory of Molecular Pharmacology, Developmetal Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland 20892 [C. J., K. W. K., Y. P.], and Research Triangle Institute, Research Triangle Park, North Carolina 27709-2194 [M. C. W., M. E. W.]

Twenty-two compounds related to camptothecin, a known inhibitor of eukaryotic topoisomerase I, were studied. The following effects on the actions of topoisomerase I were observed and were well correlated among most of the compounds studied: (a) inhibition of the first-order rate of relaxation of supercoiled DNA; (b) conversion of supercoiled DNA to nicked circles; and (c) single-strand cleavage of linear DNA at specific sites. The locations of the stimulated cleavage sites were the same for all of the active derivatives. Stereochemistry and the positions of substituents were found to be crucial for the presence or absence of effects on topoisomerase I, indicating that the compounds interact with an asymmetrical receptor site on the enzyme or enzyme-DNA complex. From the structure-activity relations, the regions of interaction between the camptothecin ring system and the receptor site were inferred. Striking correlations were observed between activity against topoisomerase I and reported activity against murine leukemias, indicating that an action on topoisomerase I is responsible for the antitumor activity of the camptothecins.

1 To whom requests for reprints should be addressed.

Received 8/11/88. Revised 11/29/88. Accepted 12/ 2/88.




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
K. Takagi, T. S. Dexheimer, C. Redon, O. Sordet, K. Agama, G. Lavielle, A. Pierre, S. E. Bates, and Y. Pommier
Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters
Mol. Cancer Ther., December 1, 2007; 6(12): 3229 - 3238.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. Dumez, A. Awada, M. Piccart, S. Assadourian, D. Semiond, G. Guetens, G. de Boeck, R. A. A. Maes, E. A. de Bruijn, and A. van Oosterom
A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours
Ann. Onc., July 1, 2006; 17(7): 1158 - 1165.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P. Luo, Q. He, X. He, Y. Hu, W. Lu, Y. Cheng, and B. Yang
Potent antitumor activity of 10-methoxy-9-nitrocamptothecin.
Mol. Cancer Ther., April 1, 2006; 5(4): 962 - 968.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. Marchand, S. Antony, K. W. Kohn, M. Cushman, A. Ioanoviciu, B. L. Staker, A. B. Burgin, L. Stewart, and Y. Pommier
A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex.
Mol. Cancer Ther., February 1, 2006; 5(2): 287 - 295.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. A. Posey III, M. W. Saif, R. Carlisle, A. Goetz, J. Rizzo, S. Stevenson, M. S. Rudoltz, J. Kwiatek, P. Simmons, E. K. Rowinsky, et al.
Phase 1 Study of Weekly Polyethylene Glycol-Camptothecin in Patients with Advanced Solid Tumors and Lymphomas
Clin. Cancer Res., November 1, 2005; 11(21): 7866 - 7871.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. C. Zamboni, L. L. Jung, M. J. Egorin, D. R. Hamburger, E. Joseph, R. Jin, S. Strychor, R. K. Ramanathan, and J. L. Eiseman
Relationship between Plasma Exposure of 9-Nitrocamptothecin and Its 9-Aminocamptothecin Metabolite and Antitumor Response in Mice Bearing Human Colon Carcinoma Xenografts
Clin. Cancer Res., July 1, 2005; 11(13): 4867 - 4874.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
A. Chatterjee, R. Digumarti, K. Katneni, V. V. Upreti, R. N. V. S. Mamidi, R. Mullangi, A. Surath, M. L. Srinivas, S. Uppalapati, S. Jiwatani, et al.
Safety, Tolerability, and Pharmacokinetics of a Capsule Formulation of DRF-1042, a Novel Camptothecin Analog, in Refractory Cancer Patients in a Bridging Phase I Study
J. Clin. Pharmacol., April 1, 2005; 45(4): 453 - 460.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
O. Soepenberg, H. Dumez, J. Verweij, D. Semiond, M. J.A. deJonge, F. A.L.M. Eskens, J. t. Steeg, J. Selleslach, S. Assadourian, G.-J. Sanderink, et al.
Phase I and Pharmacokinetic Study of Oral Irinotecan Given Once Daily for 5 Days Every 3 Weeks in Combination With Capecitabine in Patients With Solid Tumors
J. Clin. Oncol., February 1, 2005; 23(4): 889 - 898.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. E. Bates, W. Y. Medina-Perez, G. Kohlhagen, S. Antony, T. Nadjem, R. W. Robey, and Y. Pommier
ABCG2 Mediates Differential Resistance to SN-38 (7-Ethyl-10-hydroxycamptothecin) and Homocamptothecins
J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 836 - 842.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. C. Zamboni, L. L. Jung, M. J. Egorin, D. M. Potter, D. M. Friedland, C. P. Belani, S. S. Agarwala, M. M. W. Wong, M. Fakih, D. L. Trump, et al.
Phase I and Pharmacologic Study of Intermittently Administered 9-Nitrocamptothecin in Patients with Advanced Solid Tumors
Clin. Cancer Res., August 1, 2004; 10(15): 5058 - 5064.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
A. Chatterjee, R. Digumarti, R. N. V. S. Mamidi, K. Katneni, V. V. Upreti, A. Surath, M. L. Srinivas, S. Uppalapati, S. Jiwatani, S. Subramaniam, et al.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of an Orally Active Novel Camptothecin Analog, DRF-1042, in Refractory Cancer Patients in a Phase I Dose Escalation Study
J. Clin. Pharmacol., July 1, 2004; 44(7): 723 - 736.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Rapisarda, B. Uranchimeg, O. Sordet, Y. Pommier, R. H. Shoemaker, and G. Melillo
Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1: Mechanism and Therapeutic Implications
Cancer Res., February 15, 2004; 64(4): 1475 - 1482.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Antony, M. Jayaraman, G. Laco, G. Kohlhagen, K. W. Kohn, M. Cushman, and Y. Pommier
Differential Induction of Topoisomerase I-DNA Cleavage Complexes by the Indenoisoquinoline MJ-III-65 (NSC 706744) and Camptothecin: Base Sequence Analysis and Activity against Camptothecin- Resistant Topoisomerases I
Cancer Res., November 1, 2003; 63(21): 7428 - 7435.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. P. Braybrooke, E. Boven, N. P. Bates, R. Ruijter, N. Dobbs, P. D. Cheverton, H. M. Pinedo, and D. C. Talbot
Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f ), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies
Ann. Onc., June 1, 2003; 14(6): 913 - 921.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Q. Xiong, H. T. Tran, T. L. Madden, R. A. Newman, and J. L. Abbruzzese
Phase I and Pharmacological Study of Oral 9-Aminocamptothecin Colloidal Dispersion (NSC 603071) in Patients with Advanced Solid Tumors
Clin. Cancer Res., June 1, 2003; 9(6): 2066 - 2071.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Zamai, M. vandeVen, M. Farao, E. Gratton, A. Ghiglieri, M. G. Castelli, E. Fontana, R. d'Argy, A. Fiorino, E. Pesenti, et al.
Camptothecin Poly[N-(2-Hydroxypropyl) Methacrylamide] Copolymers in Antitopoisomerase-I Tumor Therapy: Intratumor Release and Antitumor Efficacy
Mol. Cancer Ther., January 1, 2003; 2(1): 29 - 40.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
B. L. Staker, K. Hjerrild, M. D. Feese, C. A. Behnke, A. B. Burgin Jr., and L. Stewart
The mechanism of topoisomerase I poisoning by a camptothecin analog
PNAS, November 26, 2002; 99(24): 15387 - 15392.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Raymond, V. Boige, S. Faivre, G.-J. Sanderink, O. Rixe, L. Vernillet, C. Jacques, M. Gatineau, M. Ducreux, and J.-P. Armand
Dosage Adjustment and Pharmacokinetic Profile of Irinotecan in Cancer Patients With Hepatic Dysfunction
J. Clin. Oncol., November 1, 2002; 20(21): 4303 - 4312.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Chatterjee, I. Schmitz, A. Krueger, K. Yeung, S. Kirchhoff, P. H. Krammer, M. E. Peter, J. H. Wyche, and P. Pantazis
Induction of Apoptosis in 9-Nitrocamptothecin-treated DU145 Human Prostate Carcinoma Cells Correlates with de Novo Synthesis of CD95 and CD95 Ligand and Down-Regulation of c-FLIPshort
Cancer Res., October 1, 2001; 61(19): 7148 - 7154.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. E. Royce, P. M. Hoff, P. Dumas, Y. Lassere, J. J. Lee, J. Coyle, M. P. Ducharme, R. De Jager, and R. Pazdur
Phase I and Pharmacokinetic Study of Exatecan Mesylate (DX-8951f): A Novel Camptothecin Analog
J. Clin. Oncol., March 1, 2001; 19(5): 1493 - 1500.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M.-L. Li, L. Horn, P. S. Firby, and M. J. Moore
Pharmacological Determinants of 9-Aminocamptothecin Cytotoxicity
Clin. Cancer Res., January 1, 2001; 7(1): 168 - 174.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
F. Kanzawa, F. Koizumi, Y. Koh, T. Nakamura, Y. Tatsumi, H. Fukumoto, N. Saijo, T. Yoshioka, and K. Nishio
In Vitro Synergistic Interactions between the Cisplatin Analogue Nedaplatin and the DNA Topoisomerase I Inhibitor Irinotecan and the Mechanism of this Interaction
Clin. Cancer Res., January 1, 2001; 7(1): 202 - 209.
[Abstract] [Full Text]

Home page
 Ann. N. Y. Acad. Sci.Home page
K. W. KOHN and Y. POMMIER
Molecular and Biological Determinants of the Cytotoxic Actions of Camptothecins: Perspective for the Development of New Topoisomerase I Inhibitors
Ann. N.Y. Acad. Sci., December 1, 2000; 922(1): 11 - 26.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
T. G. BURKE and D. BOM
Campthotecin Design and Delivery Approaches for Elevating Anti-Topoisomerase I Activities in Vivo
Ann. N.Y. Acad. Sci., December 1, 2000; 922(1): 36 - 45.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
J. J. CHAMPOUX
Structure-Based Analysis of the Effects of Camptothecin on the Activities of Human Topoisomerase I
Ann. N.Y. Acad. Sci., December 1, 2000; 922(1): 56 - 64.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
S. M. HECHT
Camptothecins as Probes of the Microenvironments of Topoisomerase I - DNA Complexes
Ann. N.Y. Acad. Sci., December 1, 2000; 922(1): 76 - 91.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
O. LAVERGNE, D. DEMARQUAY, P. G. KASPRZYK, and D. C.H. BIGG
Homocamptothecins: E-Ring Modified CPT Analogues
Ann. N.Y. Acad. Sci., December 1, 2000; 922(1): 100 - 111.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
J. W. SINGER, P. DE VRIES, R. BHATT, J. TULINSKY, P. KLEIN, C. LI, L. MILAS, R. A. LEWIS, and S. WALLACE
Conjugation of Camptothecins to Poly-(l-Glutamic Acid)
Ann. N.Y. Acad. Sci., December 1, 2000; 922(1): 136 - 150.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
J. G. LIEHR, N. J. HARRIS, J. MENDOZA, A. E. AHMED, and B. C. GIOVANELLA
Pharmacology of Camptothecin Esters
Ann. N.Y. Acad. Sci., December 1, 2000; 922(1): 216 - 223.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
C. H. TAKIMOTO and R. THOMAS
The Clinical Development of 9-Aminocamptothecin
Ann. N.Y. Acad. Sci., December 1, 2000; 922(1): 224 - 236.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
C. F. VERSCHRAEGEN, K. JAECKLE, B. GIOVANELLA, V. KNIGHT, and B. E. GILBERT
Alternative Administration of Camptothecin Analogues
Ann. N.Y. Acad. Sci., December 1, 2000; 922(1): 237 - 246.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
L. B. Saltz, J. V. Cox, C. Blanke, L. S. Rosen, L. Fehrenbacher, M. J. Moore, J. A. Maroun, S. P. Ackland, P. K. Locker, N. Pirotta, et al.
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
N. Engl. J. Med., September 28, 2000; 343(13): 905 - 914.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
J. Thiesen and I. Kramer
Physicochemical stability of irinotecan injection concentrate and diluted infusion solutions in PVC bags
Journal of Oncology Pharmacy Practice, September 1, 2000; 6(3): 115 - 121.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Santos, S. Zanetta, T. Cresteil, A. Deroussent, F. Pein, E. Raymond, L. Vernillet, M.-L. Risse, V. Boige, A. Gouyette, et al.
Metabolism of Irinotecan (CPT-11) by CYP3A4 and CYP3A5 in Humans
Clin. Cancer Res., May 1, 2000; 6(5): 2012 - 2020.
[Abstract] [Full Text]

Home page
 Mol. Pharmacol.Home page
B. Vladu, J. M. Woynarowski, G. Manikumar, M. C. Wani, M. E. Wall, D. D. Von Hoff, and R. M. Wadkins
7- and 10-Substituted Camptothecins: Dependence of Topoisomerase I-DNA Cleavable Complex Formation and Stability on the 7- and 10-Substituents
Mol. Pharmacol., February 1, 2000; 57(2): 243 - 251.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
L. Stewart, G. C. Ireton, and J. J. Champoux
A Functional Linker in Human Topoisomerase I Is Required for Maximum Sensitivity to Camptothecin in a DNA Relaxation Assay
J. Biol. Chem., November 12, 1999; 274(46): 32950 - 32960.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. M. Wadkins, P. M. Potter, B. Vladu, J. Marty, G. Mangold, S. Weitman, G. Manikumar, M. C. Wani, M. E. Wall, and D. D. Von Hoff
Water Soluble 20(S)-Glycinate Esters of 10,11-Methylenedioxycamptothecins Are Highly Active against Human Breast Cancer Xenografts
Cancer Res., July 1, 1999; 59(14): 3424 - 3428.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
G. Kohlhagen, K. D. Paull, M. Cushman, P. Nagafuji, and Y. Pommier
Protein-Linked DNA Strand Breaks Induced by NSC 314622, a Novel Noncamptothecin Topoisomerase I Poison
Mol. Pharmacol., July 1, 1998; 54(1): 50 - 58.
[Abstract] [Full Text]

Home page
 ScienceHome page
M. R. Redinbo, L. Stewart, P. Kuhn, J. J. Champoux, and W. G. Hol
Crystal Structures of Human Topoisomerase I in Covalent and Noncovalent Complexes with DNA
Science, March 6, 1998; 279(5356): 1504 - 1513.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Ohdo, T. Makinosumi, T. Ishizaki, E. Yukawa, S. Higuchi, S. Nakano, and N. Ogawa
Cell Cycle-Dependent Chronotoxicity of Irinotecan Hydrochloride in Mice
J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1383 - 1388.
[Abstract] [Full Text]

Home page
 Mol. Pharmacol.Home page
M. Valenti, W. Nieves-Neira, G. Kohlhagen, K. W. Kohn, M. E. Wall, M. C. Wani, and Y. Pommier
Novel 7-Alkyl Methylenedioxy-Camptothecin Derivatives Exhibit Increased Cytotoxicity and Induce Persistent Cleavable Complexes Both with Purified Mammalian Topoisomerase I and in Human Colon Carcinoma SW620 Cells
Mol. Pharmacol., July 1, 1997; 52(1): 82 - 87.
[Abstract] [Full Text]

Home page
 Mol. Pharmacol.Home page
N. Fujii, Y. Yamashita, T. Mizukami, and H. Nakano
Correlation between the Formation of Cleavable Complex with Topoisomerase I and Growth-Inhibitory Activity for Saintopin-Type Antibiotics
Mol. Pharmacol., February 1, 1997; 51(2): 269 - 276.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1989 by the American Association for Cancer Research.